Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » A Faster, More Accurate Way to Measure Tumor Growth
Clinical Breakthroughs

A Faster, More Accurate Way to Measure Tumor Growth

By Nora DunneSep 19, 2014
Share
Facebook Twitter Email
tumor_growth2
Using RECIST diameter measurements (right), a breast cancer liver metastatic tumor is deemed stable from baseline (top) to follow-up (bottom). But measuring by volume via tumor growth kinetics (left) indicates tumor response to treatment at follow-up.

Northwestern Medicine scientists have found a better way to measure how patients with breast cancer liver metastasis respond to treatment.

Cancer spreads to the liver in about 40 to 50 percent of patients with metastatic breast cancer. This metastasis is associated with poor prognosis, but there are therapies that attempt to control its growth and prolong patients’ short survival rates.

“It’s really important to know how patients are responding to these therapies,” said Vahid Yaghmai, MD, ’97 GME, professor in Radiology and principle investigator of the study. “If somebody has only a few months to live, you cannot wait long to find out if a tumor is shrinking. If the patient is not responding to therapy you need to change that therapy quickly.”

Currently, Response Evaluation Criteria in Solid Tumors (RECIST) is the most widely accepted method for accessing how much the size of a liver metastasis tumor has changed with therapy, typically using imaging techniques such as a CT scan. The RECIST method is simple, available and consistent across institutions, but it has significant limitations.

“The lifespan of the patient may not be long enough to accommodate what RECIST needs,” said Dr. Yaghmai. “RECIST is based on a single-diameter measurement of a tumor and it doesn’t take into account how fast the tumor is changing over time.”

RECIST assumes that tumors are spherical, when in reality some are shaped irregularly. In addition, it cannot calculate different growth rates for tumors scanned at different time intervals – for instance, every month versus every three months.

Vahid_Yaghmai
Vahid Yaghmai, MD, ’97 GME, professor in Radiology, will apply the new imaging biomarker to other types of tumors in continuing research.

Yaghmai and his colleagues validated a new method for measuring therapy response that is faster and more specific, an imaging biomarker called tumor growth kinetics. This method reports the tumor’s volume and computes how quickly a tumor is growing over time.

The findings were published in Academic Radiology.

“Growth kinetics looks at the entire shape of the tumor instead of just one diameter,” said Dr. Yaghmai. “It’s volumetric change over span of time.”

The scientists examined the same CT scans from breast cancer liver metastatic tumors before and after treatment using both RECIST and growth kinetics. They noticed discrepancies in response categorization: whether a patient’s tumor was responding, staying the same, or worsening with the treatment.

“Many lesions categorized as stable based on RECIST in fact showed response to treatment. A few that were categorized as stable by RECIST had in fact progressed and not responded to treatment,” said Dr. Yaghmai.

The growth kinetics model can help physicians evaluate tumor growth more accurately and make decisions about continuing expensive therapies on individual patients, according to the study. The scientists are applying the new assessment method to other types of tumors in continuing research.

“This kind of biomarker has great potential,” said Dr. Yaghmai. “It makes intuitive sense: Not all tumors are the same. You really have to look at the growth rate to see how an individual’s tumor is behaving.”

Cancer Research Women's Health
Share. Facebook Twitter Email

Related Posts

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.